455 Madison Avenue
New York, NY 10022
The R&D day will feature presentations by internal ProQR and external speakers on the progress of the ophthalmology pipeline, including an update on the progress of sepofarsen (formerly named QR-110) for LCA10 and QR-421a for Usher syndrome and discussion of the next therapies to enter the clinic.